Medicago develops COVID-19 vaccine candidate with its plant-based technology in 20 days

March 18, 2020
Emerging Ecosystems in Agrifood and Health More...
Very important

Medicago has rapidly developed vaccine candidates for RNA viruses previously, including a research-grade influenza vaccine in 2009. That research led to its 2019 submission of a commercializable quadrivalent influenza vaccine to Health Canada. Medicago's technology utilizes plants to produce viruslike particles that mimic viral shape and dimensions to trigger an immune response. Medicago is not the first to develop a candidate vaccine, as China and the NIH began clinical trials, but in a globalized world with inevitable and evolving diseases, companies with rapid development capabilities like Medicago have the chance to demonstrate value. Clients should aggressively pursue such developers for solutions within and outside of human health.

For the original news article, click here .

Further Reading

Oerth Bio

Company Snapshot | November 05, 2020

The company was started by a joint venture between Bayer and Arvinas, including $100 million in funds to establish the company. The company is a developer of proteolysis‑targeting chimeras (PROTACs), which exploit cellular defense mechanisms (e.g., ubiquitination) to degrade/recycle proteins in a ... To read more, click here.

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription